PropThink: Expense Cuts Ahead of a Pivotal Year for AVEO and Tivozanib

[ACN Newswire] – By Jake KingIn a move that management says will save the company more than $100M over the next three years, AVEO Oncology (NASDAQ:AVEO) cut its work force by 17% and made strategic shifts to lighten the … more

View todays social media effects on AVEO

View the latest stocks trending across Twitter. Click to view dashboard